» Articles » PMID: 27136946

Human Neutrophil Kinetics: Modeling of Stable Isotope Labeling Data Supports Short Blood Neutrophil Half-lives

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2016 May 4
PMID 27136946
Citations 146
Authors
Affiliations
Soon will be listed here.
Abstract

Human neutrophils have traditionally been thought to have a short half-life in blood; estimates vary from 4 to 18 hours. This dogma was recently challenged by stable isotope labeling studies with heavy water, which yielded estimates in excess of 3 days. To investigate this disparity, we generated new stable isotope labeling data in healthy adult subjects using both heavy water (n = 4) and deuterium-labeled glucose (n = 9), a compound with more rapid labeling kinetics. To interpret results, we developed a novel mechanistic model and applied it to previously published (n = 5) and newly generated data. We initially constrained the ratio of the blood neutrophil pool to the marrow precursor pool (ratio = 0.26; from published values). Analysis of heavy water data sets yielded turnover rates consistent with a short blood half-life, but parameters, particularly marrow transit time, were poorly defined. Analysis of glucose-labeling data yielded more precise estimates of half-life (0.79 ± 0.25 days; 19 hours) and marrow transit time (5.80 ± 0.42 days). Substitution of this marrow transit time in the heavy water analysis gave a better-defined blood half-life of 0.77 ± 0.14 days (18.5 hours), close to glucose-derived values. Allowing the ratio of blood neutrophils to mitotic neutrophil precursors (R) to vary yielded a best-fit value of 0.19. Reanalysis of the previously published model and data also revealed the origin of their long estimates for neutrophil half-life: an implicit assumption that R is very large, which is physiologically untenable. We conclude that stable isotope labeling in healthy humans is consistent with a blood neutrophil half-life of less than 1 day.

Citing Articles

Gasdermin D-dependent neutrophil extracellular traps exacerbate cytokine storm contributing to pyoderma gangrenosum pathogenesis.

Li S, Ying S, Fang H, Qiao J iScience. 2025; 28(3):111925.

PMID: 40034857 PMC: 11872606. DOI: 10.1016/j.isci.2025.111925.


On the origin of neutrophils.

Koenderman L, Tesselaar K, Vrisekoop N Cell Mol Immunol. 2025; .

PMID: 40016584 DOI: 10.1038/s41423-025-01270-1.


Factors Affecting Delayed Recovery from Neutropenia in Patients with Pancreatic Cancer Receiving Gemcitabine plus Nab-Paclitaxel.

Yoshida N, Imai S, Kawakami K, Yokokawa T, Nakamura M, Aoyama T J Cancer. 2025; 16(5):1413-1419.

PMID: 39991570 PMC: 11843245. DOI: 10.7150/jca.107359.


Mechanistic Evaluation of Anti-CD19 CAR-T Cell Therapy Repurposed in Systemic Lupus Erythematosus Using a Quantitative Systems Pharmacology Model.

Park H, Mugundu G, Singh A Clin Transl Sci. 2025; 18(2):e70146.

PMID: 39936636 PMC: 11815715. DOI: 10.1111/cts.70146.


Cancer-associated fibroblasts promote pro-tumor functions of neutrophils in pancreatic cancer via IL-8: potential suppression by pirfenidone.

Yagi T, Kagawa S, Nogi S, Taniguchi A, Yoshimoto M, Suemori K Cancer Immunol Immunother. 2025; 74(3):96.

PMID: 39904796 PMC: 11794937. DOI: 10.1007/s00262-025-03946-z.


References
1.
Painter R, DREW R, HUGHES W . Inhibition of HeLa growth by intranuclear tritium. Science. 1958; 127(3308):1244-5. DOI: 10.1126/science.127.3308.1244. View

2.
Chatta G, Price T, Stratton J, Dale D . Aging and marrow neutrophil reserves. J Am Geriatr Soc. 1994; 42(1):77-81. DOI: 10.1111/j.1532-5415.1994.tb06077.x. View

3.
Hsieh M, Everhart J, Byrd-Holt D, Tisdale J, Rodgers G . Prevalence of neutropenia in the U.S. population: age, sex, smoking status, and ethnic differences. Ann Intern Med. 2007; 146(7):486-92. DOI: 10.7326/0003-4819-146-7-200704030-00004. View

4.
Harrison W . The total cellularity of the bone marrow in man. J Clin Pathol. 1962; 15:254-9. PMC: 480393. DOI: 10.1136/jcp.15.3.254. View

5.
PATT H . A consideration of myeloid-erythroid balance in man. Blood. 1957; 12(9):777-87. View